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Rising Health Care Costs and Life-Cycle Management in
the Pharmaceutical Market
Aaron S. Kesselheim*
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston,
Massachusetts, United States of America
The problem of rising prescription drug
costs has emerged as a critical policy issue
around the world, particularly in the
United States. These costs strain the
budgets of patients and health insurers,
and directly contribute to adverse health
outcomes by reducing adherence to im-
portant medications. Drug spending is
driven by brand-name drugs, which cur-
rently account for about 20% of all
prescriptions in the US, but 80% of costs.
Brand-name drugs generally are granted
periods of market exclusivity during which
they charge high prices to account for the
initial investment in research and devel-
opment. In the case of small molecule
drugs, once the market exclusivity period
ends, competitors producing bioequivalent
generic drugs can enter the market, and
the drug price quickly falls. In this week’s
PLOS Medicine, Nathalie Vernaz and
colleagues study the consequences of this
delicate balancing act going awry due to
the cumulative effects of so-called life-cycle
management (or ‘‘evergreening’’) strate-
gies employed by the drug’s manufacturer
[1].
Life-Cycle Management in the
Pharmaceutical Market
The term ‘‘life-cycle management’’
refers to the practice of brand-name
manufacturers seeking to further extend
the market exclusivity periods for their
drugs to maintain revenue streams. Mar-
ket exclusivity extensions may be achieved
through a number of different strategies.
Some evergreening strategies offer scant
public health benefits, including slight
changes in formulation protected by
later-issued patents [2], marketing tools
such as drug coupons that reduce patients’
out-of-pocket spending on brand-name
drugs [3], and negotiating settlements with
generic companies to prevent challenges to
potentially weak or invalid patents [4].
Other evergreening strategies may provide
more measurable advantages to patients,
such as developing extended-release ver-
sions or combination products [5].
Though these latter alterations can en-
hance convenience and patient adherence,
such advantages may also be muted by
non-adherence related to the drugs’ high
costs. In all cases, follow-on products are
heavily promoted by the manufacturer to
ensure that they are prescribed over the
older versions, even if they lack evidence
of comparative efficacy or safety [6].
Life-cycle management may contribute
to rising costs at a time when government
insurance programs are cutting back on
important areas of medical coverage, but
their impact on costs or health care
delivery is not often subject to empirical
analysis. In a 2006 publication, my
colleagues and I studied three brand-name
pharmaceutical products (omeprazole,
amoxicillin/clavulanate, and metformin)
whose market exclusivities were extended
through tactics such as lawsuits against
generic competitors and patents on pe-
ripheral aspects of products. We identified
US$1.5 billion in revenue that Medicaid,
the US drug insurance program for low-
income patients, could have saved if
generic alternatives to these three medica-
tions had been available and widely used
when the patent on the active ingredient
expired [7].
Excessive Pharmaceutical
Spending in the Swiss Canton
of Geneva
Research that assesses the implications of
life-cycle management in the pharmaceuti-
cal market is rare, and the practice continues
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Linked Research Article
This Perspective discusses the fol-
lowing new study published in
PLOS Medicine:
Vernaz N, Haller G, Girardin F,
Huttner B, Combescure C, et al.
(2013) Patented Drug Extension
Strategies on Healthcare Spending:
A Cost-Evaluation Analysis. PLoS
Med 10(6): e1001460. doi:10.1371/
journal.pmed.1001460
In a cost-evaluation analysis of
pharmacy invoice data in one Can-
ton in Switzerland Nathalie Vernaz
and colleagues find that ‘‘evergre-
ening’’ strategies pursued by drug
manufacturers have been successful
in maintaining market share and
contribute to increased overall
healthcare costs.
PLOS Medicine | www.plosmedicine.org 1 June 2013 | Volume 10 | Issue 6 | e1001461as health care costs continue to accelerate,
which make the analysis by Nathalie Vernaz
and colleagues particularly timely. Studying
prescription rates in the Swiss canton of
Geneva, the authors focused on eight drugs
that demonstrate a wide array of ever-
greening strategies, including single-isomer
versions marketed in place of enantiomeric
drugs (e.g., levocetirizine and cetirizine),
combination products marketed in place of
unitary products (e.g., simvastatin/ezetimibe
and simvastatin), and slow-release formula-
tions (e.g., extended-release zolpidem and
zolpidem). Among all of these examples, the
follow-on product had no proven clinical
advantage. Vernaz et al. found that the
canton, which represents about 5% of
Switzerland’s total population, would have
saved over 30 million Euros between 2001
and 2008 if physicians had avoided the high-
cost follow-on products and instead pre-
scribed generic versions of the original
products.
In their analysis, Vernaz and colleagues
also provide some empirical insight into
two possible anti-evergreening tactics.
First, they studied the effect on communi-
ty-based prescribing of a restrictive drug
formulary imposed by the region’s large
academic medical center. They found that
requiring prescription of a generic drug
(enantiomeric cetirizine) over the follow-
on product (single-isomer levocetirizine) in
the hospital had ‘‘spill-over’’ effects in
encouraging prescribing of the lower-cost
product by community physicians, al-
though the policy only saved the health
system a small amount. By contrast, listing
the follow-on product (single-isomer
esomeprazole) over the generic precursor
(enantiomeric omeprazole) in the restric-
tive formulary led to substantial extra costs
through the same spill-over mechanism.
Second, their analysis covers a country-
wide policy enacted in 2006 to slightly
increase out-of-pocket expenses for patients
selecting brand-name drugs over generic
alternatives. Though they did not specifi-
cally test changes in prescription rates
before and after this policy change, their
results show the limited overall impact that
the policy had in stemming prescribing of
the second-generation products in their
sample.
Addressing the Public Health
Implications of Pharmaceutical
Life-Cycle Management
Given the modest effects of restrictive
formularies and co-payment changes in
combating excessive spending related to
drug life-cycle management, what other
possible solutions could reduce the nega-
tive effects of these tactics on health care
systems? Vernaz and colleagues suggest
greater investment in comparative efficacy
testing of follow-on products to better
inform physicians and patients about the
benefits—or lack thereof—of higher-cost
follow-on products like levocetirizine or
simvastatin/ezetimibe. Another more fun-
damental option would be to treat second-
generation products differently under pat-
ent statutes or other laws conferring
market exclusivity such that less innovative
follow-on products earn market exclusivity
periods shorter than that of the original
products. This pathway was recently
upheld in India, where drug patent laws
require drugs to demonstrate advances in
clinical efficacy, and not merely minor
physiochemical differences, to earn market
exclusivity [8].
With rigorously collected and analyzed
data, the study by Vernaz and colleagues
highlights an area of wasteful spending in
the health care market. While their
manuscript did not directly address patient
outcomes, their results suggest that ad-
dressing life-cycle management through
rational regulatory oversight or alterations
in patent or market exclusivity laws will be
an important way that policymakers can
achieve cost savings without adversely
affecting public health.
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